Приказ основних података о документу
Liposomes as carriers of antimicrobial drugs
dc.creator | Šiler-Marinković, Slavica | |
dc.creator | Mojović, Ljiljana | |
dc.creator | Davinić, V | |
dc.creator | Bugarski, Branko | |
dc.date.accessioned | 2021-03-10T09:40:49Z | |
dc.date.available | 2021-03-10T09:40:49Z | |
dc.date.issued | 1997 | |
dc.identifier.issn | 0363-9045 | |
dc.identifier.uri | http://TechnoRep.tmf.bg.ac.rs/handle/123456789/128 | |
dc.description.abstract | Liposome are promising drug carrier systems being developed. Their successful use in the treatment of several diseases demonstrates that a solid rationale for clinical development of liposomes as antimicrobial drug carriers can be established. There are a number of potential drug candidates for liposome encapsulation. The involvement of several biotechnology companies has culminated in the design and licensing of formulations for the treatment of certain microbial infections and cancers. Understanding of liposome behavior in the body and of the physicochemical mechanisms involved in the interaction of liposome, drug, and cellular targets is essential for their future applications. | en |
dc.publisher | Taylor & Francis Ltd, Abingdon | |
dc.rights | restrictedAccess | |
dc.source | Drug Development and Industrial Pharmacy | |
dc.title | Liposomes as carriers of antimicrobial drugs | en |
dc.type | article | |
dc.rights.license | ARR | |
dc.citation.epage | 488 | |
dc.citation.issue | 5 | |
dc.citation.other | 23(5): 483-488 | |
dc.citation.spage | 483 | |
dc.citation.volume | 23 | |
dc.identifier.doi | 10.3109/03639049709148497 | |
dc.identifier.scopus | 2-s2.0-0030900491 | |
dc.identifier.wos | A1997WV90500006 | |
dc.type.version | publishedVersion |